Risk of Cognitive Decline Associated With Paroxetine Use in Elderly Nursing Home Patients With Depression.
OBJECTIVE
This study evaluated the risk of cognitive decline associated with paroxetine use in elderly nursing home patients with depression.


METHODS
A retrospective cohort study was conducted using the 2007 to 2010 Medicare Part D claims and minimum data set (MDS) data involving new users of paroxetine and other selective serotonin reuptake inhibitors (SSRIs). The primary outcome was MDS Cognition Scale. The repeated-measures mixed model was used to examine the effect of paroxetine on cognition after controlling for other factors.


RESULTS
The baseline MDS Cognition Scale measures for paroxetine (n = 63) and other SSRI users (n =1018) were 2.02 (±1.85) and 2.50 (±2.39), respectively. The repeated-measures mixed model did not find statistically significant difference in cognition with the use of paroxetine (β = 0.02, 95% CI: -0.16 to 0.21]) when compared to other SSRIs.


CONCLUSIONS
There was no differential effect of paroxetine on cognition when compared to other SSRIs.
['Bali|Vishal|V|', 'Chatterjee|Satabdi|S|', 'Johnson|Michael L|ML|', 'Chen|Hua|H|', 'Carnahan|Ryan M|RM|', 'Aparasu|Rajender R|RR|']
D000368:Aged D060825:Cognitive Dysfunction D003863:Depression D005260:Female D006707:Homes for the Aged D006801:Humans D008297:Male D009735:Nursing Homes D017374:Paroxetine D012306:Risk D017367:Serotonin Uptake Inhibitors
cognition paroxetine elderly depression